| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Vertex Pharmaceuticals Incorporated (MX: VRTX)
VRTX Technical Analysis
5
| As on 12th Nov 2024 VRTX STOCK Price closed @ 10182.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 6425.08 & Strong Buy for SHORT-TERM with Stoploss of 5948.36 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VRTXSTOCK Price
| Open | 10182.00 | Change | Price | % |
| High | 10182.00 | 1 Day | -295.52 | -2.82 |
| Low | 10182.00 | 1 Week | 651.39 | 6.83 |
| Close | 10182.00 | 1 Month | 1046.75 | 11.46 |
| Volume | 256 | 1 Year | 4020.00 | 65.24 |
| 52 Week High 9900.85 | 52 Week Low 5665.00 | ||||
MX Mexico Most Active Stocks
| AMXL | 19.28 | -0.36% |
| FR | 480.43 | -1.58% |
| WALMEX | 51.89 | -2.68% |
| CEMEXCPO | 11.12 | 0.91% |
| NEMAKA | 1.67 | -2.34% |
| KIMBERA | 27.78 | 1.05% |
| BBAJIOO | 41.24 | -0.27% |
| BOLSAA | 33.06 | -2.68% |
| ALFAA | 15.51 | 0.00% |
| TLEVISACPO | 8.25 | 2.74% |
MX Mexico Top Gainers Stocks
MX Mexico Top Losers Stocks
| VRTX Daily Charts |
VRTX Intraday Charts |
Whats New @ Bazaartrend |
VRTX Free Analysis |
|
|
VRTX Important Levels Intraday
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
| RESISTANCE | 10182.00 |
VRTX Forecast November 2024
| 4th UP Forecast | 10785.8 |
| 3rd UP Forecast | 10592.2 |
| 2nd UP Forecast | 10472.5 |
| 1st UP Forecast | 10352.8 |
| 1st DOWN Forecast | 10011.2 |
| 2nd DOWN Forecast | 9891.52 |
| 3rd DOWN Forecast | 9771.81 |
| 4th DOWN Forecast | 9578.16 |
VRTX Weekly Forecast
| 4th UP Forecast | 10392.04 |
| 3rd UP Forecast | 10324.68 |
| 2nd UP Forecast | 10283.04 |
| 1st UP Forecast | 10241.41 |
| 1st DOWN Forecast | 10122.60 |
| 2nd DOWN Forecast | 10080.96 |
| 3rd DOWN Forecast | 10039.32 |
| 4th DOWN Forecast | 9971.96 |
VRTX Forecast2024
| 4th UP Forecast | 19455.7 |
| 3rd UP Forecast | 16481.6 |
| 2nd UP Forecast | 14643.2 |
| 1st UP Forecast | 12804.8 |
| 1st DOWN Forecast | 7559.18 |
| 2nd DOWN Forecast | 5720.79 |
| 3rd DOWN Forecast | 3882.41 |
| 4th DOWN Forecast | 908.27 |
Vertex Pharmaceuticals Incorporated ( MX Mexico Symbol : VRTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VRTX Business Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Address: 50 Northern Avenue, Boston, MA, United States, 02210
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service